Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Trial Profile

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Romidepsin (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Panniculitis; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Memorial Sloan-Kettering Cancer Center
  • Most Recent Events

    • 08 Jun 2021 Results (n=33) assessing the updated data of study evaluating the PFS of patients receiving maintenance therapy with romidepsin after autologous stem cell transplant in patients with T-cell lymphoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Feb 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
    • 26 Feb 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top